Table 6 Health outcomes and economic impact of PHiD-CV vs. PCV13 vaccination programs
|  | PCV13 (A) | PHiD-CV (B) | Difference (B−A) |
|---|---|---|---|
Health outcomes | |||
 IPD cases (acute episode) | 99 | 108 | 9 |
 All-cause pneumonia cases (acute episode) | 19,714 | 19,754 | 40 |
 AOM cases (acute episode) | 135,206 | 130,783 | −4424 |
 Deaths due to IPD/pneumonia | 19 | 19 | 0 |
Costs | |||
 Vaccination | NTD 926 465 468 | NTD 926 465 418 | − NTD 50 |
 Acute episode | |||
  IPD | NTD 7 341 171 | NTD 7 992 670 | NTD 651 499 |
  All-cause pneumonia | NTD 352 720 474 | NTD 353 278 362 | NTD 557 887 |
  AOM | NTD 189 117 177 | NTD 178 291 679 | − NTD 10 825 498 |
 Total | |||
  Undiscounted | NTD 1 475 644 291 | NTD 1 466 028 130 | - NTD 9 616 161 |
  Discounted | NTD 1 392 017 676 | NTD 1 383 217 323 | - NTD 8 800 353 |